Omer Inan

The American company's platform leverages novel, multi-sensor devices and proprietary algorithms to mine raw biosignals for unprecedented visibility into cardiac function. Cardiosense has developed an advanced signal processing pipeline to identify pre-symptomatic markers of cardiac disease, and has introduced an end-to-end patient monitoring and sensor analytics ecosystem that includes the Cardiotag sensor, a medical-grade, multi-sensor wearable device for wireless patient monitoring from in-hospital to home, and the Wavesense platform, a device-agnostic software to enable aggregation, transmission, and analytics of physiological sensor data. The company has also developed clinical AI digital biomarkers for early disease detection by applying deep learning to raw physiological waveforms. Amit K. Gupta has been the CEO of the company since 2020.

The American company's platform leverages novel, multi-sensor devices and proprietary algorithms to mine raw biosignals for unprecedented visibility into cardiac function. Cardiosense has developed an advanced signal processing pipeline to identify pre-symptomatic markers of cardiac disease, and has introduced an end-to-end patient monitoring and sensor analytics ecosystem that includes the Cardiotag sensor, a medical-grade, multi-sensor wearable device for wireless patient monitoring from in-hospital to home, and the Wavesense platform, a device-agnostic software to enable aggregation, transmission, and analytics of physiological sensor data. The company has also developed clinical AI digital biomarkers for early disease detection by applying deep learning to raw physiological waveforms. Amit K. Gupta has been the CEO of the company since 2020.

The American company's platform leverages novel, multi-sensor devices and proprietary algorithms to mine raw biosignals for unprecedented visibility into cardiac function. Cardiosense has developed an advanced signal processing pipeline to identify pre-symptomatic markers of cardiac disease, and has introduced an end-to-end patient monitoring and sensor analytics ecosystem that includes the Cardiotag sensor, a medical-grade, multi-sensor wearable device for wireless patient monitoring from in-hospital to home, and the Wavesense platform, a device-agnostic software to enable aggregation, transmission, and analytics of physiological sensor data. The company has also developed clinical AI digital biomarkers for early disease detection by applying deep learning to raw physiological waveforms. Amit K. Gupta has been the CEO of the company since 2020.

The American company's platform leverages novel, multi-sensor devices and proprietary algorithms to mine raw biosignals for unprecedented visibility into cardiac function. Cardiosense has developed an advanced signal processing pipeline to identify pre-symptomatic markers of cardiac disease, and has introduced an end-to-end patient monitoring and sensor analytics ecosystem that includes the Cardiotag sensor, a medical-grade, multi-sensor wearable device for wireless patient monitoring from in-hospital to home, and the Wavesense platform, a device-agnostic software to enable aggregation, transmission, and analytics of physiological sensor data. The company has also developed clinical AI digital biomarkers for early disease detection by applying deep learning to raw physiological waveforms. Amit K. Gupta has been the CEO of the company since 2020.